Angle set for US clearance after broader CE mark for cancer cell capture system
This article was originally published in Clinica
Executive Summary
UK diagnostic firm Angle has got the go-ahead to CE mark its Parsortix blood separation system, designed to capture and harvest rare circulating tumor cells (CTCs), for clinical use.